Exosomal Markers CD63 and CD9 in Vitiligo Before and After NB-UVB Therapy
Key facts
- Who runs it
- Amany El-Agamy Ibrahim El-Samadony
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 20 May 2024
- Ended
- 1 Jan 2026
- Type of study
- Interventional
- Treatments tested
- Narrow-Band Ultraviolet B (NB-UVB) Therapy
- Record updated
- 3 September 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients already diagnosed with vitiligo clinically and by dermoscopy
- Patients who did not receive any treatment for vitiligo for 3 months before joining the study
- Patients who accepted to be enrolled in the study and signed an informed consent
Who cannot take part
- Patients with a history of bleeding disorders or receiving anticoagulant therapy
- Patients with allergy to local anesthesia
- Patients with a history of chronic debilitating diseases, autoimmune disorders, or other systemic diseases
- Patients with other dermatological diseases
- Patients with a history of keloid or abnormal scar formation
- Pregnant or lactating females
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study evaluated the expression of the exosomal markers CD63 and CD9 in the skin of patients with vitiligo and assessed changes in their expression after narrow-band ultraviolet B (NB-UVB) therapy. Twenty patients with vitiligo were included and received NB-UVB therapy for 3 months. Clinical disease activity and severity were assessed using the Vitiligo Disease Activity (VIDA) score and the Vitiligo Area Severity Index (VASI) before and after treatment. Before treatment, skin biopsies were obtained from lesional and perilesional skin. After treatment, skin biopsies were obtained from repigmented areas. The tissue specimens were evaluated histopathologically and by immunohistochemical staining for CD63 and CD9. Twenty normal skin specimens obtained during plastic surgery were used as healthy controls for comparison.
The group in the trial
- NB-UVB TherapyTreatment being tested
Twenty patients with vitiligo received narrow-band ultraviolet B (NB-UVB) therapy for 3 months. Clinical assessment using VIDA and VASI and skin biopsies for histopathological and immunohistochemical evaluation of CD63 and CD9 were performed before and after treatment.
Treatment: Narrow-Band Ultraviolet B (NB-UVB) Therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Expression of Exosomal Markers (CD63 and CD9) in Lesional Skin of Vitiligo Patients Before and After Narrow-Band Ultraviolet B Therapy: An Immunohistochemical Study
- Record updated
- 3 September 2026